Overcoming drug resistance and treating advanced prostate cancer

Current Drug Targets

Volumn 13, Issue 10, 2012, Pages 1308-1323

  Semenas, Julius ^a   Allegrucci, Cinzia ^b   Boorjian, Stephen A ^c   Mongan, Nigel P ^b   Persson, Jenny Liao ^a  

^a LUND UNIVERSITY   (Sweden)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c MAYO CLINIC   (United States)

Author keywords

Bone nietasrasis; Novel therapy; Prostate cancer; Treatment resistance

Indexed keywords

4 [3 [4 CYANO 3 (TRIFLUOROMETHYL)PHENYL] 5,5 DIMETHYL 4 OXO 2 THIOXO 1 IMIDAZOLIDINYL] 2 FLUORO N METHYLBENZAMIDE; ABIRATERONE; ABIRATERONE ACETATE; ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ARN 509; ATRASENTAN; CABAZITAXEL; CARBOPLATIN; CETUXIMAB; CISPLATIN; CUSTIRSEN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; IPILIMUMAB; ISOSORBIDE; MEDRONATE TECHNETIUM TC 99M; MITOXANTRONE; ORTERONEL; PREDNISONE; RADIUM CHLORIDE RA 223; SILTUXIMAB; SIPULEUCEL T; STRONTIUM 89; TESTOSTERONE; THALIDOMIDE; UNCLASSIFIED DRUG;

AGING; ALCOHOL CONSUMPTION; ANGIOGENESIS; BONE MARROW; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER STAGING; CANCER STEM CELL; CELL PROLIFERATION; CELL SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; ETHNICITY; FAMILY HISTORY; GENETIC SUSCEPTIBILITY; HUMAN; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; REVIEW; SEXUALLY TRANSMITTED DISEASE; SIGNAL TRANSDUCTION; SMOKING; STEM CELL NICHE; SURVIVAL; TUMOR MICROENVIRONMENT; WNT SIGNALING PATHWAY;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS;

EID: 84866530142     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945012802429615     Document Type: Review

References (155)

1. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941. J Urol 2002; 167(2 Pt 2): 948-51; discussion 52.
2. Huggins C. The Hormone-Dependent Cancers. JAMA 1963; 186: 481-3.
3. GLOBOCAN v1.2. Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. 2008.
4. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61(4): 212-36.
5. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012; 62(1): 10-29.
6. NCI. Prostate Cancer. 2012; Available from: http://cancer.gov/cancertopics/wyntk/prostate/.
7. Pienta KJ, Esper PS. Risk factors for prostate cancer. Ann Intern Med 1993; 118(10): 793-803.
8. Bostwick DG, Burke HB, Djakiew D, et al. Human prostate cancer risk factors. Cancer 2004; 101(10 Suppl): 2371-490.
9. American Cacner Society. Cancer Facts & Figures 2009. 2009.
10. Begley L, Monteleon C, Shah RB, Macdonald JW, Macoska JA. CXCL12 overexpression and secretion by aging fibroblasts enhance human prostate epithelial proliferation in vitro. Aging cell 2005; 4(6): 291-8.
11. Bavik C, Coleman I, Dean JP, Knudsen B, Plymate S, Nelson PS. The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res 2006; 66(2): 794-802.
12. Lippman SM, Klein EA, Goodman PJ, et al. Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA 2009; 301(1): 39-51.
13. Kuriyama M, Wang MC, Papsidero LD, et al. Quantitation of prostate-specific antigen in serum by a sensitive enzyme immunoassay. Cancer Res 1980; 40(12): 4658-62.
14. Selley S, Donovan J, Faulkner A, Coast J, Gillatt D. Diagnosis, management and screening of early localised prostate cancer. Health Technol Assess 1997; 1(2): i, 1-96.
15. Frankel S, Smith GD, Donovan J, Neal D. Screening for prostate cancer. Lancet 2003; 361(9363): 1122-8.
16. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD, Walsh PC. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591-7.
17. Roberts WB, Han M. Clinical significance and treatment of biochemical recurrence after definitive therapy for localized prostate cancer. Surg Oncol 2009; 18(3): 268-74.
18. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12(20 Pt 2): 6243s-9s.
19. Loberg RD, Logothetis CJ, Keller ET, Pienta KJ. Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype. J Clin Oncol 2005; 23(32): 8232-41.
20. Muller A, Homey B, Soto H, Ge N, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature 2001; 410(6824): 50-6.
21. Taichman RS, Cooper C, Keller ET, Pienta KJ, Taichman NS, McCauley LK. Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res 2002; 62(6): 1832-7.
22. Sun YX, Schneider A, Jung Y, et al. Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res 2005; 20(2): 318-29.
23. Sun YX, Wang J, Shelburne CE, et al. Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem2003; 89(3): 462-73.
24. Sun YX, Fang M, Wang J, Cooper CR, Pienta KJ, Taichman RS. Expression and activation of alpha v beta 3 integrins by SDF-1/CXC12 increases the aggressiveness of prostate cancer cells. Prostate 2007; 67(1): 61-73.
25. Wang J, Shiozawa Y, Wang J, et al. The role of CXCR7/RDC1 as a chemokine receptor for CXCL12/SDF-1 in prostate cancer. J Biol Chem 2008;283(7): 4283-94.
26. Shiozawa Y, Havens AM, Jung Y, et al. Annexin II/annexin II receptor axis regulates adhesion, migration, homing, and growth of prostate cancer. J Cell Biochem 2008; 105(2): 370-80.
27. Grossfeld GD, Carroll PR. Prostate cancer early detection: a clinical perspective. Epidemiol Rev 2001; 23(1): 173-80.
28. Tombal B, Lecouvet F. Modern Detection of Prostate Cancer's Bone Metastasis: Is the Bone Scan Era Over? Adv Urol 2012; 2012: 893193.
29. Smith MR, Cook RJ, Coleman R, et al. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer. Urology 2007; 70(2): 315-9.
30. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004; 22(14): 2942-53.
31. Even-Sapir E, Metser U, Mishani E, Lievshitz G, Lerman H, Leibovitch I. The detection of bone metastases in patients with high-risk prostate cancer: 99mTc-MDP Planar bone scintigraphy, single-and multi-field-of-view SPECT, 18F-fluoride PET, and 18F-fluoride PET/CT. J Nucl Med 2006; 47(2): 287-97.
32. Schirrmeister H, Kuhn T, Guhlmann A, et al. Fluorine-18 2-deoxy-2-fluoro-D-glucose PET in the preoperative staging of breast cancer: comparison with the standard staging procedures. Eur J Nucl Med 2001; 28(3): 351-8.
33. Eschmann SM, Pfannenberg AC, Rieger A, et al. Comparison of 11C-choline-PET/CT and whole body-MRI for staging of prostate cancer. Nuklearmedizin 2007; 46(5): 161-8; quiz N47-8.
34. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005; 65(2): 178-87.
35. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur J Radiol 2005; 55(1): 41-55.
36. Boorjian SA, Gettman MT. Advances in robotic prostatectomy. Curr Urol Rep 2008; 9(3): 250-6.
37. Perlmutter MA, Lepor H. Androgen deprivation therapy in the treatment of advanced prostate cancer. Rev Urol 2007; 9 Suppl 1: S3-8.
38. Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 2009; 6(2): 76-85.
39. The Leuprolide Study Group. Leuprolide versus diethylstilbestrol for metastatic prostate cancer. N Engl J Med 1984; 311(20): 1281-6.
40. Vogelzang NJ, Chodak GW, Soloway MS, et al. Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group. Urology 1995; 46(2): 220-6.
41. Walsh PC. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group. J Urol 1997; 158(4): 1623-4.
42. Messing EM, Manola J, Sarosdy M, Wilding G, Crawford ED, Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 1999; 341(24): 1781-8.
43. Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group. Lancet 2000; 355(9214): 1491-8.
44. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138(2): 245-56.
45. Tran C, Ouk S, Clegg NJ, et al. Development of a secondgeneration antiandrogen for treatment of advanced prostate cancer. Science 2009; 324(5928): 787-90.
46. Clegg NJ, Wongvipat J, Joseph JD, et al. ARN-509: a novel antiandrogen for prostate cancer treatment. Cancer Res 2012; 72(6): 1494-503.
47. Tangen CM, Faulkner JR, Crawford ED, et al. Ten-year survival in patients with metastatic prostate cancer. Clin Prostate Cancer 2003; 2(1): 41-5.
48. de Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376(9747): 1147-54.
49. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351(15): 1502-12.
50. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351(15): 1513-20.
51. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26(2): 242-5.
52. Mahon KL, Henshall SM, Sutherland RL, Horvath LG. Pathways of chemotherapy resistance in castration-resistant prostate cancer. Endocr Relat Cancer 2011; 18(4): R103-23.
53. Boldt S, Weidle UH, Kolch W. The role of MAPK pathways in the action of chemotherapeutic drugs. Carcinogenesis 2002; 23(11): 1831-8.
54. Zelivianski S, Spellman M, Kellerman M, et al. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgenindependent human prostate cancer cells. Int J Cancer 2003; 107(3): 478-85.
55. Wu L, Birle DC, Tannock IF. Effects of the mammalian target of rapamycin inhibitor CCI-779 used alone or with chemotherapy on human prostate cancer cells and xenografts. Cancer Res 2005; 65(7): 2825-31.
56. Domingo-Domenech J, Oliva C, et al. Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormoneindependent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006; 12(18): 5578-86.
57. Mimeault M, Johansson SL, Vankatraman G, et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol Cancer Ther 2007; 6(3): 967-78.
58. Banerjee S, Hussain M, Wang Z, et al. In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res 2007; 67(8): 3818-26.
59. Lo Nigro C, Maffi M, Fischel JL, Formento P, Milano G, Merlano M. The combination of docetaxel and the somatostatin analogue lanreotide on androgen-independent docetaxel-resistant prostate cancer: experimental data. BJU Int 2008; 102(5): 622-7.
60. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10): 755-68.
61. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 2002; 20(13): 3001-15.
62. Metzger E, Wissmann M, Yin N, et al. LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription. Nature 2005; 437(7057): 436-9.
63. Kahl P, Gullotti L, Heukamp LC, et al. Androgen receptor coactivators lysine-specific histone demethylase 1 and four and a half LIM domain protein 2 predict risk of prostate cancer recurrence. Cancer Res 2006; 66(23): 11341-7.
64. Cai C, He HH, Chen S, et al. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell 2011; 20(4): 457-71.
65. Holzbeierlein J, Lal P, LaTulippe E, et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 2004; 164(1): 217-27.
66. Shah RB, Mehra R, Chinnaiyan AM, et al. Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res.2004; 64(24): 9209-16.
67. Koivisto P, Kononen J, Palmberg C, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res 1997; 57(2): 314-9.
68. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10(1): 33-9.
69. Tamura K, Furihata M, Tsunoda T, et al. Molecular features of hormone-refractory prostate cancer cells by genome-wide gene expression profiles. Cancer Res 2007; 67(11): 5117-25.
70. Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006; 66(5): 2815-25.
71. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68(11): 4447-54.
72. Mohler JL, Titus MA, Bai S, et al. Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 2011; 71(4): 1486-96.
73. Titus M, Tomer KB. Androgen quantitation in prostate cancer tissue using liquid chromatography tandem mass spectrometry. Methods Mol Biol 2011; 776: 47-57.
74. Darshan MS, Loftus MS, Thadani-Mulero M, et al. Taxaneinduced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res 2011; 71(18): 6019-29.
75. Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2002; 2(1): 48-58.
76. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol 2004; 5(3): 158-64.
77. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003; 22(56): 9075-86.
78. Seruga B, Ocana A, Tannock IF. Drug resistance in metastatic castration-resistant prostate cancer. Nat Rev Clin Oncol 2011; 8(1): 12-23.
79. Boddy JL, Fox SB, Han C, et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 2005; 11(21): 7658-63.
80. Rinaldo F, Li J, Wang E, Muders M, Datta K. RalA regulates vascular endothelial growth factor-C (VEGF-C) synthesis in prostate cancer cells during androgen ablation. Oncogene 2007; 26(12): 1731-8.
81. Wang G, Wang J, Sadar MD. Crosstalk between the androgen receptor and beta-catenin in castrate-resistant prostate cancer. Cancer Res 2008; 68(23): 9918-27.
82. Pollak M, Beamer W, Zhang JC. Insulin-like growth factors and prostate cancer. Cancer Metastasis Rev 1998; 17(4): 383-90.
83. Nickerson T, Chang F, Lorimer D, Smeekens SP, Sawyers CL, Pollak M. In vivo progression of LAPC-9 and LNCaP prostate cancer models to androgen independence is associated with increased expression of insulin-like growth factor I (IGF-I) and IGF-I receptor (IGF-IR). Cancer Res 2001; 61(16): 6276-80.
84. Zhu B, Kyprianou N. Transforming growth factor beta and prostate cancer. Cancer Treat Res 2005; 126: 157-73.
85. Meads MB, Gatenby RA, Dalton WS. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat Rev Cancer 2009; 9(9): 665-74.
86. Teicher BA, Herman TS, Holden SA, et al. Tumor resistance to alkylating agents conferred by mechanisms operative only in vivo. Science 1990; 247(4949 Pt 1): 1457-61.
87. Vaday GG, Hua SB, Peehl DM, et al. CXCR4 and CXCL12 (SDF-1) in prostate cancer: inhibitory effects of human single chain Fv antibodies. Clin Cancer Res 2004; 10(16): 5630-9.
88. Zhang J, Lu Y, Pienta KJ. Multiple roles of chemokine (C-C motif) ligand 2 in promoting prostate cancer growth. J Natl Cancer Inst 2010; 102(8): 522-8.
89. Qian DZ, Rademacher BL, Pittsenbarger J, et al. CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxelinduced cytotoxicity. The Prostate 2010; 70(4): 433-42.
90. Tredan O, Galmarini CM, Patel K, Tannock IF. Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 2007; 99(19): 1441-54.
91. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004; 4(6): 437-47.
92. Primeau AJ, Rendon A, Hedley D, Lilge L, Tannock IF. The distribution of the anticancer drug Doxorubicin in relation to blood vessels in solid tumors. Clin Cancer Res 2005; 11(24 Pt 1): 8782-8.
93. Kyle AH, Huxham LA, Yeoman DM, Minchinton AI. Limited tissue penetration of taxanes: a mechanism for resistance in solid tumors. Clin Cancer Res 2007; 13(9): 2804-10.
94. Heldin CH, Rubin K, Pietras K, Ostman A. High interstitial fluid pressure-an obstacle in cancer therapy. Nat Rev Cancer 2004; 4(10): 806-13.
95. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29(5): 625-34.
96. Hartmann TN, Burger JA, Glodek A, Fujii N, Burger M. CXCR4 chemokine receptor and integrin signaling co-operate in mediating adhesion and chemoresistance in small cell lung cancer (SCLC) cells. Oncogene 2005; 24(27): 4462-71.
97. Hidalgo A, Sanz-Rodriguez F, Rodriguez-Fernandez JL, et al. Chemokine stromal cell-derived factor-1alpha modulates VLA-4 integrin-dependent adhesion to fibronectin and VCAM-1 on bone marrow hematopoietic progenitor cells. Exp Hematol 2001; 29(3): 345-55.
98. Shain KH, Yarde DN, Meads MB, et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res 2009; 69(3): 1009-15.
99. Tancred TM, Belch AR, Reiman T, Pilarski LM, Kirshner J. Altered expression of fibronectin and collagens I and IV in multiple myeloma and monoclonal gammopathy of undetermined significance. J Histochem Cytochem 2009; 57(3): 239-47.
100. Kashyap V, Rezende NC, Scotland KB, et al. Regulation of stem cell pluripotency and differentiation involves a mutual regulatory circuit of the NANOG, OCT4, and SOX2 pluripotency transcription factors with polycomb repressive complexes and stem cell microRNAs. Stem Cells Dev 2009; 18(7): 1093-108.
101. Marcinkiewicz K, Scotland KB, Boorjian SA, et al. The androgen receptor and stem cell pathways in prostate and bladder cancers (review). Int J Oncol 2012; 40(1): 5-12.
102. Richardson GD, Robson CN, Lang SH, Neal DE, Maitland NJ, Collins AT. CD133, a novel marker for human prostatic epithelial stem cells. J Cell Sci 2004; 117(Pt 16): 3539-45.
103. Collins AT, Habib FK, Maitland NJ, Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci 2001; 114(Pt 21): 3865-72.
104. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP, Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci USA 2008; 105(52): 20882-7.
105. Oldridge EE, Pellacani D, Collins AT, Maitland NJ. Prostate cancer stem cells: Are they androgen-responsive? Mol Cell Endocrinol 2011. [Epub ahead of print].
106. Leong KG, Wang BE, Johnson L, Gao WQ. Generation of a prostate from a single adult stem cell. Nature 2008; 456(7223): 804-8.
107. Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005; 65(23): 10946-51.
108. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008; 133(4): 704-15.
109. Wang X, Kruithof-de Julio M, Economides KD, et al. A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature 2009; 461(7263): 495-500.
110. Jeter CR, Liu B, Liu X, et al. NANOG promotes cancer stem cell characteristics and prostate cancer resistance to androgen deprivation. Oncogene 2011; 30(36): 3833-45.
111. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008; 8(10): 755-68.
112. Birnie R, Bryce SD, Roome C, et al. Gene expression profiling of human prostate cancer stem cells reveals a pro-inflammatory phenotype and the importance of extracellular matrix interactions. Genome biology 2008; 9(5): R83.
113. Frame FM, Maitland NJ. Cancer stem cells, models of study and implications of therapy resistance mechanisms. Adv Exp Med Biol 2011; 720: 105-18.
114. Linn DE, Yang X, Sun F, et al. A Role for OCT4 in Tumor Initiation of Drug-Resistant Prostate Cancer Cells. Genes Cancer 2010; 1(9): 908-16.
115. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol 2008; 26(17): 2862-70.
116. Pienta KJ, Loberg R. The "emigration, migration, and immigration"of prostate cancer. Clin Prostate Cancer 2005; 4(1): 24-30.
117. Sabbatini P, Larson SM, Kremer A, et al. Prognostic significance of extent of disease in bone in patients with androgen-independent prostate cancer. J Clin Oncol 1999; 17(3): 948-57.
118. Jung K, Lein M, Stephan C, et al. Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: diagnostic and prognostic implications. Int J Cancer 2004; 111(5): 783-91.
119. Logothetis CJ, Lin SH. Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer 2005; 5(1): 21-8.
120. Pienta KJ, McGregor N, Axelrod R, Axelrod DE. Ecological therapy for cancer: defining tumors using an ecosystem paradigm suggests new opportunities for novel cancer treatments. Transl Oncol 2008; 1(4): 158-64.
121. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci USA 2003; 100(19): 10954-9.
122. Clines GA, Mohammad KS, Bao Y, et al. Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol 2007; 21(2): 486-98.
123. Hall CL, Bafico A, Dai J, Aaronson SA, Keller ET. Prostate cancer cells promote osteoblastic bone metastases through Wnts. Cancer Res 2005; 65(17): 7554-60.
124. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995; 1(9): 944-9.
125. NCI. Targeted Therapy. 2012; Available from: http://www.cancer.gov/dictionary?cdrid=270742.
126. Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008; 26(28): 4563-71.
127. Danila DC, Morris MJ, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010; 28(9): 1496-501.
128. ClinicalTrials. 2012; Available from: http://clinicaltrials.gov/.
129. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364(21): 1995-2005.
130. Agus DB, Stadler WM, Shevrin DH, et al. Safety, efficacy, and pharmacodynamics of the investigational agent TAK-700 in metastatic castration-resistant prostate cancer (mCRPC): Updated data from a phase I/II study. 2011 [2012.06.06]; Available from: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_d etail_view&confID=102&abstractID=81633.
131. Gross M, Higano C, Pantuck A, et al. A phase II trial of docetaxel and erlotinib as first-line therapy for elderly patients with androgen-independent prostate cancer. BMC cancer 2007; 7: 142.
132. Canil CM, Moore MJ, Winquist E, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005; 23(3): 455-60.
133. Fleming MT, Sonpavde G, Kolodziej M, et al. Association of Rash With Outcomes in a Randomized Phase II Trial Evaluating Cetuximab in Combination With Mitoxantrone Plus Prednisone After Docetaxel for Metastatic Castration-resistant Prostate Cancer. Clinical genitourinary cancer 2012; 10(1): 6-14.
134. J.S. De Bono, A. Flechon, A. Heidenreich, E. Voog, N. B. Davis, M. Qi, R. Bandekar, J. Vermeulen, G. R. Hudes,. Randomized phase II study of CNTO 328 (C), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone (M) versus M alone in metastatic castration-resistant prostate cancer (CRPC). 2010; Available from: http://www.asco.org/ascov2/ Meetings/Abstracts?&vmview=abst_detail_view&confID=73&abst ractID=30763.
135. Sternberg CN, Dumez H, Van Poppel H, et al. Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castrationresistant prostate cancer. Ann Oncol 2009; 20(7): 1264-9.
136. Sonpavde G, Matveev V, Burke JM, et al. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as firstline therapy for metastatic castration-resistant prostate cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO 2011.
137. F. Saad SJH, S. A. North, B. J. Eigl, K. N. Chi, P. Czaykowski, M. Polllak, L. Wood, E. Winquist,. A phase II randomized study of custirsen (OGX-011) combination therapy in patients with poorrisk hormone refractory prostate cancer (HRPC) who relapsed on or within six months of 1st-line docetaxel therapy. 2008; Available from: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst _detail_view&confID=55&abstractID=32032.
138. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005; 307(5706): 58-62.
139. Ning YM, Gulley JL, Arlen PM, et al. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010; 28(12): 2070-6.
140. Dahut WL, Gulley JL, Arlen PM, et al. Randomized phase II trial of docetaxel plus thalidomide in androgen-independent prostate cancer. J Clin Oncol 2004; 22(13): 2532-9.
141. Michaelson MD, Oudard S, Ou Y, et al. Randomized, placebocontrolled, phase III trial of sunitinib in combination with prednisone (SU+P) versus prednisone (P) alone in men with progressive metastatic castration-resistant prostate cancer (mCRPC). 2011; Available from: http://www.asco.org/ASCOv2/ Meetings/Abstracts?&vmview=abst_detail_view&confID=102&ab stractID=80462.
142. Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007; 110(9): 1959-66.
143. AstraZeneca. Results of Zibotentan Phase II trial in castration resistant prostate cancer. 2010; Available from: http://www.astrazeneca.com/Media/Press-releases/Article/Resultsof-Zibotentan-Phase-III-trial-in-castration-resistant-pr.
144. Bander NH, Milowsky MI, Nanus DM, Kostakoglu L, Vallabhajosula S, Goldsmith SJ. Phase I trial of 177lutetiumlabeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol 2005; 23(21): 4591-601.
145. Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: a randomised phase II trial. Lancet 2001; 357(9253): 336-41.
146. Fizazi K, Beuzeboc P, Lumbroso J, et al. Phase II trial of consolidation docetaxel and samarium-153 in patients with bone metastases from castration-resistant prostate cancer. J Clin Oncol 2009; 27(15): 2429-35.
147. Nilsson S, Franzen L, Tyrrell C, et al. A randomized, placebocontrolled, phase 2 study of radium-223 in the treatment of metastatic hormone refractory prostate cancer (HRPC): Twelve months follow-up data. 2007; Available from: http://www.asco.org/ascov2/Meetings/Abstracts?&vmview=abst_d etail_view&confID=46&abstractID=20186.
148. Yu EY, Massard C, Gross ME, et al. Once-daily dasatinib: expansion of phase II study evaluating safety and efficacy of dasatinib in patients with metastatic castration-resistant prostate cancer. Urology 2011; 77(5): 1166-71.
149. Sims RB. Development of sipuleucel-T: Autologous cellular immunotherapy for the treatment of metastatic castrate resistant prostate cancer. Vaccine 2011.
150. Graddis TJ, McMahan CJ, Tamman J, Page KJ, Trager JB. Prostatic acid phosphatase expression in human tissues. Int J Clin Exp Pathol 2011; 4(3): 295-306.
151. Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363(5): 411-22.
152. Small EJ, Tchekmedyian NS, Rini BI, Fong L, Lowy I, Allison JP. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer. Clin Cancer Res 2007; 13(6): 1810-5.
153. Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol 2012; 13(5): 501-8.
154. Yu P, Steel JC, Zhang M, et al. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model. Proc Natl Acad Sci USA 2012; 109(16): 6187-92.
155. ClinicalTrials. gov. Ipilimumab. 2012 [2012.06.10]; Available from: http://www.clinicaltrials.gov/ct2/results?term=Ipilimumab+prostate +cancer+phase+2+AND+phase+3.